A loss-of-function RNA interference screen for molecular targets in cancer

Nature

Volumn 441, Issue 1, 2006, Pages 106-110

  Ngo, Vu N ^a   Davis, R Eric ^a   Lamy, Laurence ^a   Yu, Xin ^a   Zhao, Hong ^a   Lenz, Georg ^a   Lam, Lloyd T ^a   Dave, Sandeep ^a   Yang, Liming ^b   Powell, John ^b   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; GENES; GENETIC ENGINEERING; TUMORS; VECTORS; CELLS; ENZYMES; MOLECULAR DYNAMICS; RNA;

KINASE ACTIVITY; MOLECULAR TARGETS; RNA INTERFERENCE; CANCER CELLS; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); RNA INTERFERENCE LIBRARY; THERAPEUTIC AGENTS;

RNA; ONCOLOGY;

GENE PRODUCT; I KAPPA B KINASE; PROTEIN CARD11; RETROVIRUS VECTOR; RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL10 PROTEIN, HUMAN; CARD11 PROTEIN, HUMAN; CASPASE; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; GUANYLATE CYCLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALT1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN; DOXYCYCLINE;

CANCER; GENE EXPRESSION; RNA; APOPTOSIS; ENZYME ACTIVITY; GENETIC ENGINEERING; SELF SUFFICIENCY; TAXONOMY;

ARTICLE; B CELL LYMPHOMA; BASE PAIRING; CANCER; CARD11 GENE; CELL CULTURE; CELL LINE; CELL SURVIVAL; CULTURE MEDIUM; DNA MICROARRAY; ENZYME ACTIVITY; GENE; GENE IDENTIFICATION; GENE LIBRARY; GENETIC TRANSDUCTION; GERMINAL CENTER; LARGE CELL LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAXONOMY; CELL PROLIFERATION; DRUG DESIGN; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; CANCER CELL; GENE EXPRESSION; GENETIC SCREENING; MICROARRAY ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; CARD SIGNALING ADAPTOR PROTEINS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; GUANYLATE CYCLASE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; NEOPLASM PROTEINS; NEOPLASMS; NF-KAPPA B; RNA INTERFERENCE; SUBSTRATE SPECIFICITY;

EID: 33645306041     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04687     Document Type: Article

References (30)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Paddison, P. J. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428, 427-431 (2004).
3. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
4. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
5. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
6. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
7. Lam, L. T. et al. Small molecule inhibitors of IκB-kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 11, 28-40 (2005).
8. Thome, M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nature Rev. Immunol. 4, 348-359 (2004).
9. Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862 (2003).
10. Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879 (2003).
11. Ruland, J., Duncan, G. S., Wakeham, A. & Mak, T. W. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19, 749-758 (2003).
12. Isaacson, P. G. & Du, M. Q. MALT lymphoma: from morphology to molecules. Nature Rev. Cancer 4, 644-653 (2004).
13. Zhang, Q. et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nature Genet. 22, 63-68 (1999).
14. Ruefli-Brasse, A. A., French, D. M. & Dixit, V. M. Regulation of NF-κB-dependent lymphocyte activation and development by paracaspase. Science 302, 1581-1584 (2003).
15. Ruland, J. et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33-42 (2001).
16. Xue, L. et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nature Immunol. 4, 857-865 (2003).
17. Newton, K. & Dixit, V. M. Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr. Biol. 13, 1247-1251 (2003).
18. Egawa, T. et al. Requirement for CARMA1 in antigen receptor-induced NF-κB activation and lymphocyte proliferation. Curr. Biol. 13, 1252-1258 (2003).
19. Hara, H. et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 18, 763-775 (2003).
20. Jun, J. E. et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 18, 751-762 (2003).
21. McAllister-Lucas, L. M. et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-κB induction. J. Biol. Chem. 276, 30589-30597 (2001).
22. Gaide, O. et al. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-κB activation. FEBS Lett. 496, 121-127 (2001).
23. Bertin, J. et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-assodated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-κB. J. Biol. Chem. 276, 11877-11882 (2001).
24. Zhou, H. et al. Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 427, 167-171 (2004).
25. Sun, L., Deng, L., Ea, C. K., Xia, Z. P. & Chen, Z. J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14, 289-301 (2004).
26. Kolfschoten, I. G. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858 (2005).
27. Westbrook, T. F. et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-848 (2005).
28. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
29. van de Wetering, M. et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4, 609-615 (2003).
30. Reynolds, A. et al. Rational siRNA design for RNA interference. Nature Biotechnol. 22, 326-330 (2004).